Related Experiment Video

Updated: Jun 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease

Cristiana Vitale1, Mauricio Wajngaten, Barbara Sposato

  • 1Cardiovascular Research Unit, Department of Medical Sciences, San Raffaele--TOSINVEST SANITA', via della Pisana 235, 00139 Roma, Italy.

European Heart Journal
|October 12, 2004
PubMed

Insights

Trimetazidine significantly improved left ventricular function and quality of life in elderly patients with ischaemic cardiomyopathy. This heart condition treatment enhanced systolic and diastolic function, reducing symptoms and improving overall well-being.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Elderly patients often develop ischaemic dilated cardiomyopathy due to coronary artery disease.
  • Trimetazidine is known to protect the myocardium by optimizing energy utilization during ischaemia.

Purpose of the Study:

  • To assess the impact of trimetazidine on left ventricular (LV) function in elderly individuals diagnosed with ischaemic heart disease and impaired LV function.

Main Methods:

  • A randomized trial involving 47 elderly patients (mean age 78 years) receiving standard therapy plus either trimetazidine or a placebo.
  • Echocardiographic evaluations were conducted at baseline and after a 6-month follow-up period.

Main Results:

  • Trimetazidine significantly improved left ventricular ejection fraction (LVEF), reduced LV diastolic and systolic diameters, and decreased wall motion score index compared to placebo.
  • Patients treated with trimetazidine experienced significant improvements in diastolic function, angina symptoms, NYHA class, and overall quality of life.
  • No significant changes in blood pressure or heart rate were observed between the trimetazidine and placebo groups.

Conclusions:

  • Trimetazidine, when added to standard therapy, offers significant benefits for LV systolic and diastolic function in elderly patients with ischaemic cardiomyopathy.
  • The treatment positively impacts patients' quality of life and reduces clinical symptoms associated with the condition.
Abstract

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...